CoChat

Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities

Cousin, Sophie, Italiano, Antoine · 2016 · Clinical Cancer Research

The DOI matches its Crossref record; 80 of the 83 references it cites were found in a registry or an index.

Abstract

The emergence of immune checkpoint inhibitors for solid tumor treatments represents a major oncologic advance. Since the approval of ipilimumab, a cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, for the treatment of metastatic melanoma, many drugs, especially those targeting PD-1/PD-L1, have demonstrated promising antitumor effects in many types of cancer. By reactivating the immune system, these immunotherapies have led to the development of new toxicity profiles, also called immune-related adverse events (irAE). IrAEs can involve many organ systems, and their management is radically different from that of cytotoxic drugs; irAEs require immunosuppressive treatments, such as corticoids or TNFα antibody. In addition, the occurrence of irAEs has raised significant questions. Here, we summarize progress that has been made toward answering these questions, focusing on (i) the impact of immunotherapy dose on irAE occurrence, (ii) the correlation between irAE and patient outcome, (iii) the safety of immune checkpoint inhibitors in patients already treated for autoimmune disease, and (iv) the suspected effect on tumor growth of steroids used for the management of irAEs. Clin Cancer Res; 22(18); 4550–5. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2569

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 80 references

Research works printed but not linked: 2

  1. Borghaei, 2015, Nivolumab versus Docetaxel in advanced nonsquamous non–small cell Lung cancer, N Engl J Med, 373, 1627, 10.1056/nejmoa1507643 · DOI · Paper page
  2. Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti–CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/s1470-2045(15)70076-8 · DOI · Paper page

Cited by

See all 86

Metadata

Authors
Cousin, S., & Italiano, A.
Affiliations
  • Institut Bergonié (FR)
  • 1Early Phase Trials Unit, Institut Bergonié, Bordeaux, France.
Venue
Clinical Cancer Research
Published
2016-09-15
Volume
22
Issue
18
Pages
4550-4555
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2490874882
Cited by
83
References
83
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 2
FWCI
1.27
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
immune checkpoint inhibitors, immune-related adverse events, CTLA-4, PD-1/PD-L1, ipilimumab, immunotherapy toxicity, immunosuppressive therapy, corticosteroids, TNF-alpha inhibitors, autoimmune disease, patient outcomes, tumor growth
MeSH terms
Antineoplastic Agents, Immunological, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Immunomodulation, Molecular Targeted Therapy, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2569
The paper
Cousin, S., & Italiano, A. (2016). Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.